Janney Montgomery Scott
SPRO icon

Janney Montgomery Scott’s Spero Therapeutics SPRO Stock Holding History

Janney Montgomery Scott’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,500
Closed -$222K – 2432
2022
Q1 		$222K Hold
25,500
– – ﹤0.01% 2029
2021
Q4 		$408K Sell
25,500
-500
-2% -$7.94K ﹤0.01% 1836
2021
Q3 		$479K Buy
26,000
+2,500
+11% +$40.1K ﹤0.01% 1685
2021
Q2 		$328K Buy
23,500
+8,500
+57% +$119K ﹤0.01% 1868
2021
Q1 		$221K Buy
15,000
+3,000
+25% +$52.8K ﹤0.01% 2012
2020
Q4 		$233K Sell
12,000
-2,500
-17% -$39K ﹤0.01% 2018
2020
Q3 		$162K Hold
14,500
– – ﹤0.01% 1950
2020
Q2 		$196K Hold
14,500
– – ﹤0.01% 1838
2020
Q1 		$117K Buy
14,500
+1,000
+7% +$8.81K ﹤0.01% 1764
2019
Q4 		$130K Buy
+13,500
New +$146K ﹤0.01% 1993

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janney Montgomery Scott's SPRO Position: Q2 2022 in Review

Janney Montgomery Scott sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 25,500 shares — an estimated $222K sold.

Janney Montgomery Scott first reported a position in SPRO in Q4 2019 and held it in 10 quarters. The position peaked at $479K in Q3 2021. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Janney Montgomery Scott reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Janney Montgomery Scott sold 25,500 Spero Therapeutics shares in Q2 2022, an estimated $222K.
  • Janney Montgomery Scott first reported a position in Spero Therapeutics in Q4 2019 and held it in 10 quarters.
  • Janney Montgomery Scott's Spero Therapeutics position peaked at $479K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Janney Montgomery Scott's 13F filing for Q2 2022, filed 3 Aug 2022.